Eli Lilly to buy Centessa in $6.3 billion deal for sleep medicines
Eli Lilly is acquiring Centessa Pharmaceuticals for approximately $6.3 billion, with an additional contingent value right potentially increasing the deal to $7.8 billion. This strategic move aims to bolster Lilly's offerings in the sleep-wake diso...
By Reuters |
Agencies
Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at about $6.3 billion to expand into treatments for sleep-wake disorders.
The U.S. drugmaker has offered Frankfurt-listed Centessa $38-per-share in cash. Centessa's U.S.-listed shares jumped 46% in premarket trading.
Lilly has also offered one non-transferrable contingent value right (CVR) of about $9, taking the total deal value to up to $7.8 billion.
The U.S. drugmaker has offered Frankfurt-listed Centessa $38-per-share in cash. Centessa's U.S.-listed shares jumped 46% in premarket trading.
Lilly has also offered one non-transferrable contingent value right (CVR) of about $9, taking the total deal value to up to $7.8 billion.
Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
Related Articles
Eli Lilly launches cancer drug Tanstrive in IndiaADVERTISEMENT
